Table 1 Intratumoral PD-L2 expression and TILs in relation to clinicopathologic characteristics of PDAC

From: A PD-L2-based immune marker signature helps to predict survival in resected pancreatic ductal adenocarcinoma

Intratumoral expression
		PD-L2			CD3			CD8			FOXP3
	N	Low (0–1)	High (2–3)	P	Low	High	P	Low	High	P	Low	High	P
Sex
Male	158	125	33	0.540	113	45	0.805	129	29	0.066	131	27	0.502
Female	147	112	35		107	40		131	16		126	21
Age
< 60	106	86	20	0.340	76	30	0.138	86	20	0.139	88	18	0.663
≥60	199	152	47		144	55		174	25		169	30
Location
Head	181	136	45	0.348	130	51	0.913	153	28	0.885	147	34	0.030
Body	62	49	13		44	18		53	9		59	3
Tail	62	52	10		46	16		54	8		51	11
Grade
Well	16	14	2	0.361	10	6	0.677	14	2	0.908	13	3	0.941
Moderate	175	140	35		127	48		150	25		148	27
Low	114	85	29		83	31		96	18		96	18
Tumor stage
T1	51	43	8	0.494	33	18	0.252	40	11	0.212	45	6	0.694
T2	176	135	41		133	43		149	27		147	29
T3	78	60	18		54	24		70	8		65	13
Node stage
N0	154	125	29	0.020	109	45	0.343	137	17	0.007	133	21	0.562
N1	108	79	29		76	32		83	25		88	20
N2	43	40	3		35	8		35	8		36	7
AJCC stage
I	124	103	21	0.154	90	34	0.274	109	15	0.071	108	16	0.509
II	138	101	37		95	43		111	27		113	25
III	43	34	9		35	8		40	3		36	7

TILs tumor infiltrating lymphocytes, PDAC pancreatic ductal adenocarcinoma

Back to article page